A FIRST-IN-HUMAN SINGLE-DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF LY2165766 INCLUDING BRAIN DOPAMINE D2 RECEPTOR OCCUPANCY BY POSITRON EMISSION TOMOGRAPHY (PET)
Completed
- Conditions
- schizophrenia10039628
- Registration Number
- NL-OMON33530
- Lead Sponsor
- Chorus LRL (devisie van Eli Lilly)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 38
Inclusion Criteria
healthy male
Part A: 18 - 65 year.
Part B: 35 - 65 year
Part C: 35 - 65 year
Exclusion Criteria
Relevant disease in medical history
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method